Assuntos
Artrite , Cistos , Doenças Pulmonares Intersticiais , Humanos , Criança , Pulmão , Artrite/diagnóstico por imagemAssuntos
Neoplasias do Sistema Nervoso Central , Doenças Desmielinizantes , Linfoma , Sistema Nervoso Central/patologia , Neoplasias do Sistema Nervoso Central/diagnóstico por imagem , Neoplasias do Sistema Nervoso Central/patologia , Doenças Desmielinizantes/patologia , Humanos , Linfoma/diagnóstico por imagem , Linfoma/patologia , Imageamento por Ressonância MagnéticaRESUMO
BACKGROUND: DiaRem score consists in preoperative model for predicting remission of type 2 diabetes mellitus in obese patients who underwent gastric bypass. AIM: To evaluate the applicability of DiaRem comparing the scores obtained preoperatively with remission of T2DM after surgery. METHOD: Preoperative parameters such as age, use of insulin, oral hypoglycemic agents and glycated hemoglobin, were retrospectively evaluated in diabetic patients undergoing gastric bypass during the period between July 2012 to July 2013. Through these data the DiaRem score were applied. The results of fasting blood glucose and glycated hemoglobin were requested prospectively. RESULTS: Were selected 70 patients; the remission of T2DM after surgery was found in 42 (60%) and no remission in 28 (40%). Checking the final score, it was observed that: from 0 to 2 points, 94.1% of patients remitted completely; between 3 and 7 had remission in 68.9%, of which 42.8% complete; from 8 to 12, 57.1% achieved complete remission; between 13 to 17, 87.5% did not achieve remission and was not seen this complete remission group; between 18 to 22, 88.9% were not remitted. CONCLUSION: The DiaRem score showed appropriate tool to assess remission of T2DM in obese patients who will undergo gastric bypass.
Assuntos
Diabetes Mellitus Tipo 2/complicações , Derivação Gástrica , Obesidade Mórbida/complicações , Obesidade Mórbida/cirurgia , Adulto , Fatores Etários , Diabetes Mellitus Tipo 2/sangue , Feminino , Hemoglobinas Glicadas/análise , Humanos , Hipoglicemiantes/uso terapêutico , Insulina/uso terapêutico , Masculino , Pessoa de Meia-Idade , Modelos Teóricos , Obesidade Mórbida/sangue , Valor Preditivo dos Testes , Cuidados Pré-Operatórios , Prognóstico , Indução de Remissão , Estudos RetrospectivosRESUMO
Background:DiaRem score consists in preoperative model for predicting remission of type 2 diabetes mellitus in obese patients who underwent gastric bypass.Aim:To evaluate the applicability of DiaRem comparing the scores obtained preoperatively with remission of T2DM after surgery.Method:Preoperative parameters such as age, use of insulin, oral hypoglycemic agents and glycated hemoglobin, were retrospectively evaluated in diabetic patients undergoing gastric bypass during the period between July 2012 to July 2013. Through these data the DiaRem score were applied. The results of fasting blood glucose and glycated hemoglobin were requested prospectively.Results:Were selected 70 patients; the remission of T2DM after surgery was found in 42 (60%) and no remission in 28 (40%). Checking the final score, it was observed that: from 0 to 2 points, 94.1% of patients remitted completely; between 3 and 7 had remission in 68.9%, of which 42.8% complete; from 8 to 12, 57.1% achieved complete remission; between 13 to 17, 87.5% did not achieve remission and was not seen this complete remission group; between 18 to 22, 88.9% were not remitted.Conclusion:The DiaRem score showed appropriate tool to assess remission of T2DM in obese patients who will undergo gastric bypass.
Racional: Escore DiaRem consiste em modelo pré-operatório de predição de remissão de diabete melito tipo 2 (DM2) em pacientes obesos que serão submetidos exclusivamente ao bypass gástrico.Objetivo: Avaliar a aplicabilidade desse escore comparando a pontuação obtida pré-operatoriamente com a remissão de DM2 após realização da operação.Método: Foram avaliados retrospectivamente, dados clínicos e laboratoriais pré-operatórios necessários para aplicar o escore (idade, uso de insulinoterapia, uso de hipoglicemiantes orais e hemoglobina glicada) de pacientes diabéticos submetidos à gastroplastia laparotômica do tipo bypass, e após um a dois anos de acompanhamento pós-operatório, verificou-se a remissão ou não do DM2.Resultados:Selecionou-se 70 pacientes; a remissão completa foi encontrada em 35 (50%), parcial em sete (10%) e não houve remissão em 28 (40%). Verificando a pontuação final, foi visto que as expectativas lançadas pelo escore DiaRem foram atingidas, pois o grupo de pacientes que alcançou a remissão foi o mesmo que obteve as menores pontuações.Conclusão: O escore DiaRem mostrou-se ferramenta apropriada para avaliar remissão de DM2 em obesos que serão submetidos ao bypass gástrico.
Assuntos
Adulto , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , /complicações , Derivação Gástrica , Obesidade Mórbida/complicações , Obesidade Mórbida/cirurgia , Fatores Etários , /sangue , Hemoglobinas Glicadas/análise , Hipoglicemiantes/uso terapêutico , Insulina/uso terapêutico , Modelos Teóricos , Obesidade Mórbida/sangue , Valor Preditivo dos Testes , Cuidados Pré-Operatórios , Prognóstico , Indução de Remissão , Estudos RetrospectivosRESUMO
The antimycobacterial activity of (-)-cubebin (1), hinokinin (2), and some of their semisynthetic derivatives, namely (-)-O-acetyl-cubebin (3), (-)-O-methyl-cubebin (4), (-)-O-(N,N-dimethylamine-ethyl)-cubebin (5) and (-)-6,6'-dinitrohinokinin (6), was evaluated against Mycobacterium tuberculosis (ATCC 27294), M. kansasii (ATCC 12478), and M. avium (ATCC 15769). The MIC values ranged from 31.25 to 2000 microg/mL. Among the evaluated compounds, 2 displayed a MIC value of 62.5 microg/mL against M. tuberculosis, while 3 and 4 displayed MIC values of 62.5 and 31.25 microg/mL, respectively, against M. avium. All compounds were inactive against M. kansasii. These are promising results concerning the search for biologically active natural products, highlighting that new approaches to the prevention, treatment, and cure of tuberculosis are extremely important.